ABSTRACT
Analizar los cambios del Índice de rigidez arterial ambulatorio y el Péptido Natriurético cerebral tipo B, ( IRAA y BNP) en 52 pacientes hipertensos que asistieron a la consulta Cardio-metabólica del Hospital Militar Dr. Carlos Arvelo, Caracas, Venezuela, entre enero y junio del 2015, antes y después del tratamiento antihipertensivo. Métodos: se realizó un ensayo clínico pareado, abierto, aleatorizado, donde los pacientes hipertensos de novo que cumplieron con los criterios de inclusión fueron asignados de forma aleatoria al grupo de trabajo. Se realizó seguimiento por tres meses posterior al inicio del tratamiento antihipertensivo. Se comparó la presión arterial media según el MAPA, IRAA y BNP en el primer y tercer mes en el grupo para evaluar éxito en alcanzar el control, así como también, se analizó la frecuencia de complicaciones cardiovasculares y muerte durante el estudio. Resultados: se encontró diferencia significativa entre los valores de AASI y BNP antes y después de 3 meses de tratamiento antihipertensivo (p= < 0,01) independientemente del tratamiento antihipertensivo utilizado en el grupo de estudio. Conclusión: El AASI y BNP mostraron ser modificables con el tratamiento antihipertensivo, y que ésta modificación se relaciona positivamente con los cambios de algunos de los parámetros del MAPA, como la Carga, la Presión de Pulso y la Presión Arterial Sistólica(AU)
to analyze the changes of AASI and BNP in hypertensive patients attending the Cardiometabolic consultation of Hospital Dr. Carlos Arvelo Military (Caracas, Venezuela) between January and June 2015, before and after antihypertensive treatment. Methods: this is a paired trial, open, clinical, randomized trial, where hypertensive patients recently diagnosed were randomly assigned to the study group. Monitoring was done three months after initiation of antihypertensive treatment. The mean blood pressure was compared according to ABPM, AASI and BNP from the first to the third month in the group to evaluate success in achieving control, and the frequency of cardiovascular complications and death during the study were also analyzed. Results: A significant difference was found between the values of AASI and BNP before and after 3 months of antihypertensive treatment ( p = <0,01) regardless of which antihypertensive treatment was used in the study group. Conclusion: The AASI and BNP were modified with antihypertensive treatment, and this change was positively related to changes in some parameters of the ABP Monitoring, such as Load, Pulse Pressure and Systolic. Blood Pressure(AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Vascular Stiffness/physiology , Hypertension/physiopathology , Antihypertensive Agents/administration & dosage , Cardiovascular Diseases , Internal MedicineABSTRACT
Objective To observe the effect of levosimendan in the treatment of pulmonary heart disease patients with heart failure.Methods 60 patients were randomly divided into treatment group and control group.The treatment group used levosimendan.The control group used digitalis.We observed the NT -PROBNP, echocardio-graphic and clinical efficacy.Adverse drug reactions were observed too.Results The significantly effect of the treat-ment group was 22 cases(73%),and effective was 8 cases (27%).The significant effect of the control group was 14 cases (43%),and effective was 16 cases (57%).The levels of NT-PROBNP and pulmonary artery pressure in the treatment group were ( 416 ±311 ) pg/mL, ( 51 ±9 ) mmHg after 1 month treatment, which in the control group were (1 516 ±250) ng/mL,(57 ±10) mmHg.The efficacy of the treatment group was better than the control group (χ2 =4.44,P<0.05),the levels of NT-PROBNP and pulmonary artery pressure were lower(t=15.10,2.44,all P<0.05).Conclusion The levosimendan had effects on the pulmonary heart disease patients with heart failure.
ABSTRACT
Objective To investigate the efficacy of milrinone micropump in treatment of chronic heart failure(CHF),and the influence to the level of amino-terminal B-type natriuretic peptide precursor(NT-proBNP) in serum.Methods 120 cases with CHF were selected,they were randomly divided into the observation group and the control group according to a random number table.The patients of the control group were treated with standardized anti -conventional treatment of heart failure according to their heart function,the patients of the observation group were given milrinone micropump on the basis of the standardized anti-conventional treatment of heart failure.The efficacy of clinical conditions 1 week after treatment and NT-proBNP levels in serum before and after treatment were compared between two groups.Results The clinical efficacy of the observation group was 95.00％,which was higher than 76.67％ of the control group,the difference was statistically significant(x2 =8.67,P ＜ 0.05).The serum level of NT-proBNP of the observation group was (38.9 ± 9.2) ng/L,which was significantly lower than (86.3 ± 32.4) ng/L of the control group,the difference was statistically significant (t =9.86,P ＜ 0.05).Conclusion Milrinone micro pump used in the treatment of CHF can significantly improve the clinical efficacy,and lower the serum level of NT-proBNP,improve heart function,it is safe and reliable and worth to application in the clinical.